TABLE 1.
Virus | IC50, mean ± SD (μM) (fold change) |
|||||
---|---|---|---|---|---|---|
SQV | IDV | APV | LPV | ATV | TPV | |
HIV104pre | 0.0073 ± 0.0014 | 0.042 ± 0.003 | 0.029 ± 0.002 | 0.034 ± 0.002 | 0.002 ± 0.0004 | 0.16 ± 0.03 |
HIVA | 0.075 ± 0.001 (10) | 0.59 ± 0.04 (14) | 0.074 ± 0.013 (3) | 0.26 ± 0.014 (8) | 0.024 ± 0.003 (12) | 0.36 ± 0.007 (2) |
HIVB | 0.36 ± 0.001 (49) | >1 (>24) | >1 (>34) | >1 (>29) | 0.28 ± 0.01 (140) | 0.18 ± 0.01 (1) |
HIVC | 0.032 ± 0.002 (4) | >1 (>24) | 0.37 ± 0.01 (11) | >1 (>29) | 0.034 ± 0.004 (17) | 0.17 ± 0.04 (1) |
HIVG | 0.030 ± 0.001 (4) | 0.36 ± 0.1 (9) | 0.43 ± 0.04 (15) | 0.26 ± 0.04 (8) | 0.043 ± 0.022 (22) | 0.24 ± 0.08 (2) |
HIVTM | 0.26 ± 0.04 (36) | >1 (>24) | 0.32 ± 0.007 (11) | >1 (>29) | 0.065 ± 0.008 (33) | 0.38 ± 0.05 (2) |
HIVMM | 0.22 ± 0.01 (29) | >1 (>24) | 0.32 ± 0.03 (11) | 0.59 ± 0.004 (17) | 0.21 ± 0.02 (105) | 0.35 ± 0.007 (2) |
HIVSS | 0.17 ± 0.004 (23) | >1 (>24) | 0.13 ± 0.01 (4) | 0.21 ± 0.04 (6) | 0.032 ± 0.006 (16) | 0.41 ± 0.14 (3) |
HIVJSL | 0.30 ± 0.02 (41) | >1 (>24) | 0.78 ± 0.1 (27) | >1 (>29) | 0.43 ± 0.04 (215) | 0.23 ± 0.05 (1) |
HIVEV | 0.36 ± 0.05 (49) | 0.25 ± 0.02 (6) | >1 (>34) | >1 (>29) | 0.43 ± 0.04 (215) | 0.066 ± 0.016 (0.4) |
HIVES | 0.45 ± 0.01 (62) | >1 (>24) | >1 (>34) | 0.41 ± 0.01 (12) | 0.032 ± 0.004 (16) | 0.34 ± 0.01 (2) |
HIV13-52 | 0.029 ± 0.003 (4) | 0.32 ± 0.03 (7) | 0.030 ± 0.003 (1) | 0.22 ± 0.1 (6) | 0.021 ± 0.007 (11) | 0.10 ± 0.01 (0.6) |
IC50s were determined by using PHA-PBMCs as target cells, and the inhibition of p24 Gag protein production by each drug was used as the endpoint. Numbers in parentheses represent the n-fold change of the IC50 for each isolate compared to the IC50 for wild-type strain HIV104pre. All assays were conducted in duplicate or triplicate, and the data shown represent mean values ±1 standard deviation derived from the results of three independent experiments. PHA-PBMCs were derived from a single donor in each independent experiment.